Antibody Drug Conjugate News and Research

RSS

Femtogenix announces new data on ADCs containing reduced potency payloads in solid tumor models

Femtogenix Ltd, a UK biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate payloads, today announced data demonstrating the potent efficacy and favorable toxicity profile of a reduced potency analogue from its Pyridinobenzodiazepine ADC payload platform in solid tumor models.

From Pheon Therapeutics 29 Oct 2019

Femtogenix announces efficacy, toxicity data of new DNA-binding ADC payload molecules

Femtogenix Ltd, a UK biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate (ADC) payloads, today announced data verifying the favorable toxicity profile and potent efficacy of its Pyridinobenzodiazepine (PDD) ADC payload platform in tumor cell models.

14 Oct 2019

UK health secretary “seriously” considering mandating childhood vaccination

The UK is “looking very seriously” at making vaccinations compulsory for all children attending school in England, according to the health secretary Matt Hancock.

1 Oct 2019

Innovative technology could help treat cancer more selectively and effectively

Treating cancer more selectively and more effectively - this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie and the Ludwig-Maximilians-Universität München.

9 Aug 2019

Innovative technology could treat cancer more selectively and effectively

9 Aug 2019

New chemoimmunotherapy regimen for aggressive form of lymphoma gets FDA approval

A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration for patients with an aggressive form of non-Hodgkin lymphoma.

24 Jun 2019

Persistent poverty endangers health in 20% of UK children

A recent study shows that one in five children in the UK have a higher risk of developing adolescent mental health disorders or physical illness because of persistent poverty. This alarming scenario comes from a new paper published in the Archives of Disease in Childhood.

13 Jun 2019

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

10 Jun 2019

Antibody-drug conjugate effectively targets surface protein in childhood neuroblastomas

Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells.

14 Mar 2019

Porvair Sciences to improve the diagnosis and treatment of ovarian cancer

Porvair Sciences reports on its involvement in a new £2.6 million project led by Swansea University (UK) that aims to dramatically improve the diagnosis and treatment of ovarian cancer.

From Chromatrap® - Porvair Sciences Ltd 27 Feb 2019

Lab-Scale Clarification of Mammalian Cell Cultures Expressing Recombinant Antibodies

Tina Stoschek and Marcus Gerlach discuss maximizing mAb generation using lab-scale clarification of cell cultures expressing recombinant antibodies.

From Sartorius 23 Jan 2019

AI pathology diagnostic tool developed using deep learning technology from Olympus

Since 2017, Olympus Corporation has participated in a joint research program that has the potential to help streamline the workload of clinical pathologists, called “A New Approach to Develop Computer-Aided Diagnosis Using Artificial Intelligence (AI) for Gastric Biopsy Specimens”.

From Evident Corporation - Life Sciences 18 Oct 2018

Personalized goal setting to improve dementia care

Dementia is a health condition that affects your memory in ways that can make it difficult to carry out your usual daily tasks. The most common cause of dementia is Alzheimer's disease, which causes abnormal changes that kill brain cells.

11 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Forbius receives $18.75 million grant from CPRIT for Phase 2a development of AVID100

Forbius announced today that it has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas.

25 Aug 2018

New Spectrum digitizers are ideal for use in multi-channel applications

Spectrum Instrumentation has added twelve new products to its family of LXI-based digitizerNETBOX data acquisition instruments. Designed specifically for situations where multiple signals need to be acquired, stored and analyzed, users can select from models that provide 24, 32, 40 or even 48 fully synchronized channels.

From Spectrum Instrumentation GmbH 27 Jul 2018

Minakem's new high-class production facility extends capacity to develop and manufacture HPAPI compounds

Minakem, the CDMO division of Minafin, specialized in custom development and manufacturing of building blocks, GMP intermediates and Active Pharmaceutical Ingredients, today announces it is in the final qualification run to open a new closed-controlled environment high containment production facility in August.

22 Jun 2018

Targeted 'click-to-release' chemotherapy leads to potent antitumor activity in mice

Antibody Drug Conjugates are relatively new anti-cancer drugs. They consist of an antibody to which a cell-killing molecule (chemotherapy) is attached. Antibodies can recognize and bind to certain receptors (the 'hands' on the outside of a cell) in a very targeted way.

4 May 2018

Abzena selects Sartorius Stedim Biotech as preferred equipment supplier in the U.S

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

From Sartorius 9 Feb 2018

UCSF researchers find new way to attack common drivers of 'undruggable' cancers

Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer.

24 Jan 2018